Syngene International Limited (SYNGENE.NS)
INR 627.95
(-0.96%)
INR 627.95
(-0.96%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 6.46 Billion INR | -0.29% |
| 2022 | 6.46 Billion INR | 49.72% |
| 2021 | 4.31 Billion INR | 11.32% |
| 2020 | 3.87 Billion INR | 0.88% |
| 2019 | 3.84 Billion INR | 2.34% |
| 2018 | 3.75 Billion INR | 39.64% |
| 2017 | 2.68 Billion INR | -0.77% |
| 2016 | 2.71 Billion INR | -9.77% |
| 2015 | 3 Billion INR | 39.24% |
| 2014 | 2.15 Billion INR | 10.79% |
| 2013 | 1.94 Billion INR | 31.2% |
| 2012 | 1.48 Billion INR | 59.23% |
| 2011 | 932 Million INR | 75.52% |
| 2010 | 531 Million INR | 24.65% |
| 2009 | 426 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 662 Million INR | -69.32% |
| 2024 Q2 | 1.29 Billion INR | 95.77% |
| 2023 Q4 | 2.15 Billion INR | 41.32% |
| 2023 Q3 | 1.52 Billion INR | -10.75% |
| 2023 FY | 6.44 Billion INR | -0.29% |
| 2023 Q1 | 1.33 Billion INR | -44.72% |
| 2023 Q2 | 1.71 Billion INR | 28.26% |
| 2022 FY | 6.46 Billion INR | 49.72% |
| 2022 Q2 | 1.41 Billion INR | 57.27% |
| 2022 Q3 | 1.53 Billion INR | 8.4% |
| 2022 Q1 | 901 Million INR | -44.0% |
| 2022 Q4 | 2.41 Billion INR | 57.1% |
| 2021 Q3 | 1.05 Billion INR | 15.64% |
| 2021 Q4 | 1.6 Billion INR | 53.24% |
| 2021 FY | 4.31 Billion INR | 11.32% |
| 2021 Q1 | 749 Million INR | -49.46% |
| 2021 Q2 | 908 Million INR | 21.23% |
| 2020 Q4 | 1.48 Billion INR | 51.84% |
| 2020 Q1 | 721 Million INR | -49.4% |
| 2020 FY | 3.87 Billion INR | 0.88% |
| 2020 Q2 | 802 Million INR | 11.23% |
| 2020 Q3 | 976 Million INR | 21.7% |
| 2019 Q1 | 721 Million INR | -42.23% |
| 2019 Q2 | 834 Million INR | 15.67% |
| 2019 Q4 | 1.42 Billion INR | 65.12% |
| 2019 Q3 | 863 Million INR | 3.48% |
| 2019 FY | 3.84 Billion INR | 2.34% |
| 2018 Q3 | 973 Million INR | -11.55% |
| 2018 Q2 | 1.1 Billion INR | 78.57% |
| 2018 Q1 | 616 Million INR | -3.75% |
| 2018 Q4 | 1.24 Billion INR | 28.26% |
| 2018 FY | 3.75 Billion INR | 39.64% |
| 2017 Q2 | 832 Million INR | 29.8% |
| 2017 Q4 | 640 Million INR | -29.82% |
| 2017 Q1 | 641 Million INR | -7.5% |
| 2017 FY | 2.68 Billion INR | -0.77% |
| 2017 Q3 | 912 Million INR | 9.62% |
| 2016 Q1 | 622 Million INR | -31.95% |
| 2016 Q4 | 693 Million INR | -17.5% |
| 2016 Q3 | 840 Million INR | 7.97% |
| 2016 Q2 | 778 Million INR | 25.08% |
| 2016 FY | 2.71 Billion INR | -9.77% |
| 2015 Q1 | 562 Million INR | -20.06% |
| 2015 FY | 3 Billion INR | 39.24% |
| 2015 Q4 | 914 Million INR | 33.04% |
| 2015 Q3 | 687 Million INR | 10.75% |
| 2015 Q2 | 620.3 Million INR | 10.37% |
| 2014 FY | 2.15 Billion INR | 10.79% |
| 2014 Q4 | 703 Million INR | 24.42% |
| 2014 Q1 | 410.8 Million INR | 0.0% |
| 2014 Q2 | 440.7 Million INR | 7.28% |
| 2014 Q3 | 565 Million INR | 28.21% |
| 2013 FY | 1.94 Billion INR | 31.2% |
| 2012 FY | 1.48 Billion INR | 59.23% |
| 2011 FY | 932 Million INR | 75.52% |
| 2010 FY | 531 Million INR | 24.65% |
| 2009 FY | 426 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Biocon Limited | 50.83 Billion INR | 87.276% |
| Blue Jet Healthcare Limited | 3.37 Billion INR | -91.802% |
| Concord Biotech Limited | 6.26 Billion INR | -3.292% |
| Dishman Carbogen Amcis Limited | -413 Million INR | 1666.102% |
| Jubilant Ingrevia Limited | 2.93 Billion INR | -120.004% |
| Lyka Labs Limited | 29.13 Million INR | -22103.913% |
| Panacea Biotec Limited | - INR | -Infinity% |
| Piramal Pharma Limited | 4.31 Billion INR | -49.892% |
| SMS Lifesciences India Limited | 359.47 Million INR | -1699.306% |
| Supriya Lifescience Limited | 1.57 Billion INR | -311.542% |
| TAKE Solutions Limited | -213.49 Million INR | 3129.65% |
| Zota Health Care Limited | -129.79 Million INR | 5083.204% |